FindTrial
Sign In

NBI-98854

DRUG10 trials

Sponsors

Neurocrine Biosciences

Conditions

Tardive DyskinesiaTourette Syndrome

Phase 1

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
CompletedNCT02256475
Neurocrine BiosciencesTourette Syndrome
Start: 2014-09-30End: 2015-12-31Updated: 2016-01-07

Phase 2

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
CompletedNCT01267188
Neurocrine BiosciencesTardive Dyskinesia
Start: 2011-01-31End: 2011-03-31Target: 10Updated: 2011-04-20
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
CompletedNCT01393600
Neurocrine BiosciencesTardive Dyskinesia
Start: 2011-08-31End: 2012-02-29Updated: 2017-08-10
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
CompletedNCT01688037
Neurocrine BiosciencesTardive Dyskinesia
Start: 2012-09-30End: 2013-10-31Updated: 2017-11-08
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
CompletedNCT01733121
Neurocrine BiosciencesTardive Dyskinesia
Start: 2012-12-31End: 2013-12-31Updated: 2017-08-10
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
CompletedNCT02581865
Neurocrine BiosciencesTourette Syndrome
Start: 2015-11-30End: 2016-12-31Updated: 2020-05-07
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
CompletedNCT02679079
Neurocrine BiosciencesTourette Syndrome
Start: 2016-03-23End: 2017-04-14Updated: 2021-01-15
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
TerminatedNCT03732534
Neurocrine BiosciencesTourette Syndrome
Start: 2018-10-17End: 2019-02-18Updated: 2022-04-19

Phase 3

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
CompletedNCT02274558
Neurocrine BiosciencesTardive Dyskinesia
Start: 2014-10-31End: 2016-07-31Updated: 2017-07-11
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
CompletedNCT02405091
Neurocrine BiosciencesTardive Dyskinesia
Start: 2015-03-31End: 2017-03-31Updated: 2018-11-30

Related Papers

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
Psychopharmacology Bulletin2025-08-1223 citations
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
Psychopharmacology Bulletin2025-08-1223 citations
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
Psychopharmacology Bulletin2025-08-1213 citations
Improvements Over Time with Valbenazine in Elderly Adults (≥65 Years) with Tardive Dyskinesia: Post Hoc Analyses of 2 Long-Term Studies.
2025-04-232 citations
Valbenazine Improves Tardive Dyskinesia with or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
CNS Spectrums2024-10-01
Sustained Treatment Response with Long-Term Valbenazine in Patients with Tardive Dyskinesia (P11-11.012)
Neurology2023-04-25
Sustained Treatment Response With Long-Term Valbenazine in Patients With Tardive Dyskinesia
CNS Spectrums2023-04-01
Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia (1235)
Neurology2021-04-13
Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia
CNS Spectrums2021-04-011 citations
Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Analyses from Two Long-Term Clinical Trials
CNS Spectrums2021-04-01
Parkinsonism secondary to use of valbenazine and reversal with the addition of levodopa: A Case Report (1183)
Neurology2020-04-143 citations
123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia
CNS Spectrums2020-04-012 citations
140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses
CNS Spectrums2020-04-01
139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study
CNS Spectrums2020-04-01
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia
Journal of Clinical Psychopharmacology2019-11-0128 citations
The effects of valbenazine on tardive dyskinesia in older and younger patients
International Journal of Geriatric Psychiatry2019-10-1610 citations
Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference
Movement Disorders2019-06-2429 citations
Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials (P4.8-035)
Neurology2019-04-09
77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia
CNS Spectrums2019-02-012 citations
67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder
CNS Spectrums2019-02-01

13 more papers not shown